Sign inCreate account

Report workspace tools

NCT03316651UNKNOWNanonymous

A Multicenter Clinical Study of the Sequential Therapy With Whole Lung Lavage/Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Severe Autoimmune Pulmonary Alveolar Proteinosis in China

Sponsor

Source record

Dai Huaping

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

GM-CSF

Indication / condition

AI-normalized

Pulmonary Alveolar Proteinosis

Intervention

Source record

GM-CSF

Source & freshness

Source record

NCT ID

NCT03316651

Original source

ClinicalTrials.gov

Source last updated

Oct 20, 2017

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03316651

Title

A Multicenter Clinical Study of the Sequential Therapy With Whole Lung Lavage/Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Severe Autoimmune Pulmonary Alveolar Proteinosis in China

Sponsor

Dai Huaping

Status

UNKNOWN

Phase

PHASE2

Condition raw

Pulmonary Alveolar Proteinosis, Treatment

Condition normalized

Pulmonary Alveolar Proteinosis, Treatment

Modality raw

small molecule

Modality normalized

small molecule

Target raw

GM-CSF

Target normalized

GM-CSF

Interventions

GM-CSF

Public preview

Source record

The purpose of the study is to evaluate the effectiveness of the sequential therapy with whole lung Lavage (WLL)/inhaling granulocyte-macrophage colony stimulating factor, compared to WLL only, for adult patients with severe autoimmune pulmonary alveolar proteinosis in China over a two-year period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter Clinical Study of the Sequential Therapy With Whole Lung Lavage/Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Severe Autoimmune Pulmonary Alveolar Proteinosis in China

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03316651

Status

UNKNOWN

Phase

PHASE2

Sponsor

Dai Huaping

Executive brief

Investment-Ready Snapshot

The purpose of the study is to evaluate the effectiveness of the sequential therapy with whole lung Lavage (WLL)/inhaling granulocyte-macrophage colony stimulating factor, compared to WLL only, for adult patients with severe autoimmune pulmonary alveolar proteinosis in China over a two-year period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 20, 2017
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03316651

Indication

Pulmonary Alveolar Proteinosis

Modality

small molecule

Target

GM-CSF

Intervention

GM-CSF

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.